Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
LOS ANGELES, July 08, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced today that the results of its latest clinical study were published Friday in the journal Scientific Reports....
-
- Arbutus to receive $20 million in gross proceeds before advisory fees while retaining significant downstream economics - Runway extended with non-dilutive capital WARMINSTER, Pa., July 02,...
-
SACRAMENTO, CA, July 02, 2019 (GLOBE NEWSWIRE) -- The True Life Companies (TTLC) has recently closed on the sale of 69 homesites to KB Home in the community of Galt, CA, a southern suburb of...
-
Santa Monica, CA, July 01, 2019 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to...
-
BURNABY, British Columbia, June 26, 2019 (GLOBE NEWSWIRE) -- D-Wave Systems Inc., the leader in quantum computing systems, software, and services, today announced the general availability of D-Wave...
-
Santa Monica, CA, June 25, 2019 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing technology platform...
-
SALT LAKE CITY, June 25, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that The Pharmacogenomics Journal published the...
-
Visiongain has launched a new electronics report Small Satellite Market 2019-2029: Forecasts by Classification (nano satellite, micro satellite, mini satellite, pico satellite and femto satellite),...
-
Santa Monica, CA, June 20, 2019 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical device company developing a proprietary biomedical signal...
-
- AB-729 is a subcutaneously-administered RNAi agent targeting HBV replication and HBsAg antigen production - Supports corporate objective to combine AB-729 with AB-506, Arbutus’ proprietary oral...